Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "CAS"

1848 News Found

Star Health Insurance settles claims of Rs.11,500 Cr
News | August 23, 2025

Star Health Insurance settles claims of Rs.11,500 Cr

The company has improved access to quality healthcare for seniors across both urban and rural areas


Dr. Lal PathLabs pioneers AI integration in cancer diagnosis in India
Digitisation | August 21, 2025

Dr. Lal PathLabs pioneers AI integration in cancer diagnosis in India

The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases


SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
Healthcare | August 21, 2025

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction

The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries


AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
News | August 17, 2025

AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease

Phase 1 dosing is expected to finish by the end of 2025


UFlex posts Q1 FY26 PAT at Rs. 58 Cr
News | August 17, 2025

UFlex posts Q1 FY26 PAT at Rs. 58 Cr

The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization


Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
News | August 17, 2025

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase


Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs
News | August 16, 2025

Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs

Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs


Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
News | August 13, 2025

Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr

EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent


Sandoz launches renewable energy partnership
Sustainability | August 12, 2025

Sandoz launches renewable energy partnership

The agreement complements other PPAs for Sandoz production sites globally